The development and clinical application of ErbB2-targeted therapeutics, such as trastuzumab and lapatinib, have significantly improved clinical outcomes in patients with ErbB2-positive (ErbB2+) breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.